SERO Serologicals (MM)

Serologicals Corporation (NASDAQ: SERO) today announced that five finalists from 83 entries have been chosen for its Upstate Group 2006 Young Cell Signaller Award. Entries were submitted as abstracts by Ph.D. students and first time post-doctorates competing to win $17,000 worth of support funding for their laboratory's reagents, a personal cash prize of $8,500 and a trophy. The finalists will present their work on Tuesday, June 13th in the morning for judging by an experienced scientific panel to include two of the world's most cited scientists, Sir Philip Cohen and Professor Doreen Cantrell. Each entrant will give a 25 - 30 minute presentation, followed by a five-minute question and answer period. The winner will be announced at the conference dinner on Tuesday, June 13th in the evening. The finalists and their presentations are: Rashu Bhargava Seth, from the UT Southwestern Medical Center, presenting "Understanding Host Antiviral Signaling Pathways." Marzena Bienko, from the John Wolfgang Goethe University, Frankfurt, presenting "Novel Ubiquitin-Binding Domains in Y-Family Polymerases Regulate Translesion Synthesis." Kate Jeffrey, from the Garvan Institute of Medical Research, presenting "PAC-1 Phosphatase: as key positive regulator of immune cell function and inflammatory responses." Nina Jones, from the Samuel Lunenfeld Research Institute, presenting "Nck Adaptors Link Nephrin to the Actin Cytoskeleton of Kidney Podocytes." Omar Perez, from the Stanford University School of Medicine, presenting "Activation State Analysis in Single Cells: a systems biology approach to understanding intracellular mechanisms." Serologicals Corporation President and CEO David Dodd commented on the finalists, "These young people represent the future of our industry in medical research. I congratulate all of them and wish them continued success in their future work." The Third Annual Cell Signalling Symposium will be held June 11-14, 2006, at the Apex City Quay Hotel, Dundee, U.K. It is co-sponsored by Upstate and the MRC Protein Phosphorylation Unit at the University of Dundee. The focus for this three day, not-for-profit meeting is 'Signalling in the Innate and Adaptive Immune Systems'. Registration is open to all scientists with an interest in cell signalling, drug discovery and disease. For more about the symposium or to register, visit www.upstate.com/symposia/2006, call +44 (0) 1382 561600 or e-mail registration@upstate.com. Upstate is a leading research discovery provider of the highest quality cell signaling products and services to the life science market. Its customers are biomedical researchers at drug discovery companies and academic institutions in the key disciplines of oncology, immunology, proteomics, cardiology and neurology. Known for its enabling, innovative solutions to help understand the biology of kinases, chromatin, g-proteins and cytokines, Upstate's advanced cell biology tools - drug screening services, enzymes, state specific antibodies, siRNA kits, multiplex assays are used by thousands of customers worldwide, every day to accelerate improving human health. Upstate, a Serologicals company, is headquartered in Temecula, California, and offices in Dundee, Scotland. For more information, please visit our website www.upstate.com. Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA, is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Serologicals' customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs approximately 1,000 people worldwide and reported revenues of $275 million in 2005. For more information, please visit our website: www.serologicals.com This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" and similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. These risks and uncertainties include, without limitation, our ability to continue to introduce new products at a rapid pace and the acceptance of such products by our customers. Serologicals is a registered trademark of Serologicals Royalty Company.